What are the considerations for using romosozumab in an elderly patient (≥65 years) with severe osteoporosis and high fracture risk who has no history of myocardial infarction, stroke, or other major cardiovascular events?

Romosozumab Considerations for Elderly Patients

Romosozumab is an appropriate and highly effective treatment option for elderly patients (≥65 years) with severe osteoporosis and high fracture risk who have no history of myocardial infarction or stroke, and should be strongly considered as first-line therapy in this population given its superior fracture reduction efficacy compared to other agents. 1

Key Clinical Considerations

Patient Selection and Cardiovascular Screening

The FDA black-box warning specifically contraindicates romosozumab in patients who have had a myocardial infarction or stroke within the preceding year 1. However, your elderly patient without prior cardiovascular events falls outside this contraindication. The pharmacokinetic data demonstrates no clinically significant differences based on age (20-89 years) 2, making elderly patients appropriate candidates.

Before initiating therapy, you must:

• Document absence of recent (within 1 year) MI or stroke
• Assess current cardiovascular risk factors (hypertension, hyperlipidemia, diabetes)
• Consider that age alone does not preclude use, but cardiovascular history does

Efficacy Profile in High-Risk Patients

Romosozumab demonstrates exceptional fracture reduction that surpasses other osteoporosis therapies 1:

• 73% reduction in vertebral fractures versus placebo at 12 months
• 34% reduction in vertebral fractures versus alendronate at 12 months
• 38% reduction in hip fractures at 24 months (when followed by antiresorptive)
• 19% reduction in nonvertebral fractures at 24 months

The AACE guidelines position romosozumab as a "rescue drug" for patients at very high fracture risk 1, which aligns with your elderly patient's severe osteoporosis profile.

Treatment Duration and Sequential Therapy

Critical treatment algorithm:

1. Limit romosozumab to exactly 12 months (Grade B recommendation) 3
2. Immediately transition to bisphosphonate or denosumab without any washout period 3, 1
3. No drug holiday is appropriate after romosozumab 3

This sequential approach is mandatory because bone density gains reverse rapidly after discontinuation 1. The ACR guidelines specifically emphasize that sequential treatment is recommended to prevent rebound bone loss and vertebral fractures after discontinuation 4, 5.

Cardiovascular Safety Nuances

The cardiovascular signal requires careful interpretation:

Evidence showing concern:

• The ARCH trial (N=4,093) showed more serious cardiovascular events with romosozumab versus alendronate 1
• One meta-analysis found increased risk of 4-point MACE (HR 1.39,95% CI 1.01-1.90) 6

Evidence showing reassurance:

• The increased risk did not persist beyond 12 months and was small 1
• Recent real-world data from 2026 shows lower cardiovascular risk compared to teriparatide in CKD patients (HR 0.82 for MACE) 7
• Another 2026 real-world analysis demonstrated lower hazard ratios for cardiovascular events versus teriparatide (HR 0.441 for 4-point MACE) 8
• Comparison with denosumab in CKD showed lower 1095-day cumulative cardiovascular risk (12.6% vs 18.8%) 9

For your elderly patient without prior cardiovascular events: The benefit-risk ratio favors treatment given the severe osteoporosis and high fracture risk, but shared decision-making regarding cardiovascular considerations is appropriate.

Monitoring Requirements

During the 12-month treatment course:

• BMD testing at 1-2 year intervals to confirm therapeutic response 3, 1
• Bone turnover markers (P1NP and CTX) can assess compliance and efficacy 3
  • Expect P1NP to peak at 145% above baseline at 2 weeks, then decline 2
  • Expect CTX to decrease 55% at 2 weeks, remaining suppressed 2
• Monitor for injection site reactions (4-5% incidence) 10

Practical Administration

• Dosing: 210 mg subcutaneous monthly for 12 months 2
• Steady-state achieved by month 3 2
• Can be used in patients with prior bisphosphonate exposure (demonstrated superior BMD gains versus teriparatide even after 3+ years of bisphosphonate therapy) 1
• No dose adjustment needed for age or renal impairment (including ESRD on dialysis) 2

Common Pitfalls to Avoid

1. Do not use romosozumab without planning sequential therapy - this negates the fracture benefit
2. Do not extend beyond 12 months - not approved and no additional benefit demonstrated
3. Do not use in patients with recent (<1 year) MI or stroke - absolute contraindication
4. Do not delay transition to antiresorptive - bone loss occurs rapidly after discontinuation

Comparison to Alternative Anabolic Agents

While teriparatide and abaloparatide are alternatives, romosozumab offers:

• Greater BMD increases (lumbar spine: 17.7% vs 12.9% for teriparatide) 1
• Dual mechanism (increases formation AND decreases resorption) 1, 11
• More rapid fracture risk reduction 11

The 2024 evidence-based guideline for osteoporosis in men notes that sequential therapy starting with bone-forming agents followed by antiresorptives should be considered for very high fracture risk 12, a principle that applies to your elderly female patient.

Final Algorithm for Your Patient

Given severe osteoporosis, high fracture risk, age ≥65, and no cardiovascular contraindications:

1. ✓ Initiate romosozumab 210 mg subcutaneous monthly
2. ✓ Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800 IU/day) 3
3. ✓ Monitor BMD and bone turnover markers
4. ✓ Complete exactly 12 months of therapy
5. ✓ Immediately transition to denosumab or bisphosphonate
6. ✓ Continue antiresorptive long-term without holiday

This approach maximizes fracture risk reduction while respecting the cardiovascular safety profile in your appropriately selected elderly patient.